FY2025 · period end Dec '25 · from the 10-K filed Apr 30, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0.01B | $0.01B | $0.01B | $0.01B | $0.00B |
| Gross Profit | negative: -$0.01B | negative: -$0.01B | negative: -$0.01B | negative: -$0.01B | negative: -$0.00B |
| Operating Income | negative: -$0.08B | negative: -$0.06B | negative: -$0.06B | negative: -$0.12B | negative: -$0.06B |
| Net Income | negative: -$0.08B | negative: -$0.05B | negative: -$0.06B | negative: -$0.11B | negative: -$0.06B |
| EPS (Diluted) | negative: -$1.16 | negative: -$0.91 | negative: -$1.08 | negative: -$2.17 | negative: -$1.28 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $0.16B | $0.21B | $0.22B | $0.25B | $0.36B |
| Total Liabilities | $0.02B | $0.02B | $0.02B | $0.04B | $0.07B |
| Stockholders' Equity | $0.14B | $0.19B | $0.20B | $0.22B | $0.29B |
| Cash & Equivalents | $0.05B | $0.04B | $0.06B | $0.04B | $0.07B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | negative: -$0.04B | negative: -$0.04B | negative: -$0.04B | negative: -$0.04B | negative: -$0.04B |
| Capital Expenditures | $0.00B | $0.00B | $0.00B | $0.01B | $0.02B |
| Free Cash Flow | negative: -$0.04B | negative: -$0.04B | negative: -$0.05B | negative: -$0.05B | negative: -$0.06B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | negative: -98.2% | negative: -94.0% | negative: -66.6% | negative: -80.2% | negative: -116.0% |
| Operating Margin | negative: -6.0% | negative: -5.0% | negative: -6.3% | negative: -1372.2% | negative: -4720.7% |
| Net Margin | negative: -5.8% | negative: -4.7% | negative: -6.1% | negative: -1320.2% | negative: -4739.1% |
| Return on Equity | negative: -45.6% | negative: -27.8% | negative: -29.5% | negative: -44.5% | negative: -23.6% |
| Return on Assets | negative: -40.3% | negative: -25.0% | negative: -25.7% | negative: -36.7% | negative: -20.6% |
| Debt / Equity | 0.02× | 0.03× | 0.02× | 0.02× | 0.00× |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 20-F | 0001213900-26-050191 | Dec 31, 2025 | Apr 30, 2026 | Apr 30, 2026 20:03 UTC | EDGAR |
| 20-F | 0001213900-25-030318 | Dec 31, 2024 | Apr 9, 2025 | Apr 9, 2025 20:29 UTC | EDGAR |
| 20-F | 0001213900-24-034697 | Dec 31, 2023 | Apr 22, 2024 | Apr 22, 2024 13:23 UTC | EDGAR |
| 20-F | 0001213900-23-034133 | Dec 31, 2022 | May 1, 2023 | May 1, 2023 10:37 UTC | EDGAR |
| 20-F | 0001213900-22-022912 | Dec 31, 2021 | May 2, 2022 | May 2, 2022 12:14 UTC | EDGAR |
| 20-F | 0001213900-21-020392 | Dec 31, 2020 | Apr 6, 2021 | Apr 6, 2021 20:05 UTC | EDGAR |
Direct links to SEC EDGAR. NNOX has additional filings available on the SEC site.
5 numbers Nano-X Imaging Ltd. later changed — same XBRL tag, both filings linked.
Net Cash Provided by (Used in) Operating Activities·FY 2020
Minor restatementwas-$21.5M
Revised down in a 20-F.
Accrued Liabilities, Current·As of Dec 31, 2020
Major restatementwas$3.5M
Revised down in a 20-F.
Marketable Securities, Realized Gain (Loss)·FY 2021
Major restatementwas$90.3M
Revised up in a 20-F.
Lease, Cost·FY 2022
Notable restatementwas$937K
Revised up in a 20-F.
Deferred Tax Liabilities, Gross·As of Dec 31, 2023
Notable restatementwas$19.2M
Revised up in a 20-F.
NNOX is not the only one.
See every restatement we've found across the market — or get an alert the next time NNOX revises a number.
Restatements are detected by comparing every vintage of a fact across all of Nano-X Imaging Ltd.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows NNOX's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling Nano-X Imaging Ltd. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on NNOX yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on NNOX and publish the result to your public profile.
Ask about Nano-X Imaging Ltd.
Continue in Workspace — cited answers on NNOX, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs